The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice
- PMID: 1651159
The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice
Abstract
Many human tumors of epithelial origin contain cells overexpressing the epidermal growth factor (EGF) receptor, and there is convincing evidence that cancer cell growth is correlated with the loss of the normal regulation of the EGF receptor signal transduction pathway. Some cancers are clearly dependent on activation of the EGF receptor for their proliferation. Recently, a class of compounds, tyrphostins, which inhibit the protein tyrosine kinase activity of the growth factor receptor, have been described. In this report, we have examined the antiproliferative effects of potent new tyrphostins on a well-characterized human squamous cell carcinoma in vitro and in vivo. We found that two of these compounds (RG-13022 and RG-14620) suppressed not only EGF-stimulated cancer cell proliferation in vitro but also tumor growth in nude mice. RG-13022 also increased the life span of these tumor-bearing nude mice. When administered to tumor-bearing nude mice together with monoclonal antibodies to the EGF receptor at a suboptimal dose which had no effect alone, inhibition of tumor growth was markedly enhanced. These data suggest that tyrphostins have potential as anticancer agents.
Similar articles
-
Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.Cancer Res. 1992 Jul 1;52(13):3636-41. Cancer Res. 1992. PMID: 1617636
-
Antiproliferative effects of tyrosine kinase inhibitors (tyrphostins) on human bladder and renal carcinoma cells.J Surg Res. 1995 Dec;59(6):675-80. doi: 10.1006/jsre.1995.1222. J Surg Res. 1995. PMID: 8538164
-
Alterations in EGF-dependent proliferative and phosphorylation events in squamous cell carcinoma cell lines by a tyrosine kinase inhibitor.Anticancer Drug Des. 1994 Aug;9(4):311-29. Anticancer Drug Des. 1994. PMID: 7916899
-
Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.J Pharm Belg. 1997 Mar-Apr;52(2):88-96. J Pharm Belg. 1997. PMID: 9193132 Review.
-
Tyrosine kinases as targets for cancer therapy.Eur J Cancer. 2002 Sep;38 Suppl 5:S11-8. doi: 10.1016/s0959-8049(02)80598-6. Eur J Cancer. 2002. PMID: 12528768 Review.
Cited by
-
Transforming growth factor alpha (TGF-alpha) increases cell number in a human pancreatic cancer cell line but not in normal mouse pancreas.Int J Pancreatol. 2000 Dec;28(3):199-205. doi: 10.1385/IJGC:28:3:199. Int J Pancreatol. 2000. PMID: 11373057
-
Chemotherapy for high-grade gliomas.Br J Cancer. 2000 Apr;82(8):1371-80. doi: 10.1054/bjoc.1999.1075. Br J Cancer. 2000. PMID: 10780513 Free PMC article. Review. No abstract available.
-
Herbimycin A, a pp60c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo.J Clin Invest. 1993 Jun;91(6):2791-5. doi: 10.1172/JCI116521. J Clin Invest. 1993. PMID: 8514886 Free PMC article.
-
Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells.Br J Cancer. 1993 Nov;68(5):939-46. doi: 10.1038/bjc.1993.458. Br J Cancer. 1993. PMID: 8105867 Free PMC article.
-
Inhibition of pancreatic cancer cell growth in vitro by the tyrphostin group of tyrosine kinase inhibitors.Br J Cancer. 1993 Dec;68(6):1122-6. doi: 10.1038/bjc.1993.491. Br J Cancer. 1993. PMID: 8260363 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources